[Immunossupresive drugs in renal transplantation]

Area of Science:

• Nephrology
• Immunology
• Transplantation Medicine

Background:

• Modern immunosuppressive agents significantly reduce acute renal allograft rejection, achieving high one-year graft survival rates.
• Long-term kidney transplant survival has seen limited improvement, with chronic allograft nephropathy and patient death being major concerns after the first year.
• Adverse effects of immunosuppressants, including nephrotoxicity and hypertension, contribute to chronic allograft nephropathy and impact long-term outcomes.

Purpose of the Study:

• To review the current challenges in long-term kidney transplant survival.
• To discuss the role of immunosuppressive drug adverse effects in chronic allograft nephropathy.
• To highlight current trends in immunosuppressive therapy, including drug withdrawal and dose reduction strategies.

Main Methods:

• Literature review of immunosuppressive strategies in kidney transplantation.
• Analysis of factors contributing to long-term graft loss and patient mortality.
• Discussion of current trends in immunosuppressive drug regimens.

Main Results:

• Optimal immunosuppression achieves 95% one-year graft survival, but long-term survival is suboptimal.
• Chronic allograft nephropathy and recipient death are primary causes of graft loss beyond the first year.
• Drug-induced toxicities like nephrotoxicity, hypertension, and diabetes mellitus are significant complications.

Conclusions:

• Individualized immunosuppressive regimens are crucial to balance acute rejection prevention and minimize adverse effects.
• Current trends focus on reducing or withdrawing nephrotoxic agents like calcineurin inhibitors and glucocorticosteroids.
• Addressing chronic allograft nephropathy and drug-related complications is essential for improving long-term kidney transplant outcomes.